Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra Robrecht

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Blood|July 31, 2024
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 studyOthman Al-Sawaf, Sandra Robrecht, Can Zhang, et al.
The Lancet. Oncology|September 5, 2020
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trialOthman Al-Sawaf, Can Zhang, Maneesh Tandon, et al.
Leukemia|February 12, 2020
Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study groupManuela A Hoechstetter, Raymonde Busch, Barbara Eichhorst, et al.
Leukemia|February 20, 2020
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trialCarmen D Herling, Florence Cymbalista, Carolin Groß-Ophoff-Müller, et al.
Hemasphere|February 20, 2020
Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)Nadine Kutsch, Jasmin Bahlo, Sandra Robrecht, et al.
Blood|January 13, 2026
The Landscape and Evolution of Clonal Hematopoiesis in Chronic Lymphocytic LeukemiaOthman Al-Sawaf, Benjamin Nick Locher, Friederike Christen, et al.
Blood Advances|December 8, 2025
Impact of Perforin 1 A91V germline background in patients with aggressive B-NHL treated with R-CHOPOnur Cetin, Igor Age Kos, Evi Regitz, et al.
The New England Journal of Medicine|June 6, 2019
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting ConditionsKirsten Fischer, Othman Al-Sawaf, Jasmin Bahlo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2024
End Point Surrogacy in First-Line Chronic Lymphocytic LeukemiaFlorian Simon, Rudy Ligtvoet, Sandra Robrecht, et al.
Blood|September 4, 2025
Acalabrutinib treatment for older (≥80 years old) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trialFlorian Simon, Rudy Ligtvoet, Jan-Paul Bohn, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Blood|July 31, 2024
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 studyOthman Al-Sawaf, Sandra Robrecht, Can Zhang, et al.
The Lancet. Oncology|September 5, 2020
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trialOthman Al-Sawaf, Can Zhang, Maneesh Tandon, et al.
Leukemia|February 12, 2020
Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study groupManuela A Hoechstetter, Raymonde Busch, Barbara Eichhorst, et al.
Leukemia|February 20, 2020
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trialCarmen D Herling, Florence Cymbalista, Carolin Groß-Ophoff-Müller, et al.
Hemasphere|February 20, 2020
Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)Nadine Kutsch, Jasmin Bahlo, Sandra Robrecht, et al.
Blood|January 13, 2026
The Landscape and Evolution of Clonal Hematopoiesis in Chronic Lymphocytic LeukemiaOthman Al-Sawaf, Benjamin Nick Locher, Friederike Christen, et al.
Blood Advances|December 8, 2025
Impact of Perforin 1 A91V germline background in patients with aggressive B-NHL treated with R-CHOPOnur Cetin, Igor Age Kos, Evi Regitz, et al.
The New England Journal of Medicine|June 6, 2019
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting ConditionsKirsten Fischer, Othman Al-Sawaf, Jasmin Bahlo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2024
End Point Surrogacy in First-Line Chronic Lymphocytic LeukemiaFlorian Simon, Rudy Ligtvoet, Sandra Robrecht, et al.
Blood|September 4, 2025
Acalabrutinib treatment for older (≥80 years old) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trialFlorian Simon, Rudy Ligtvoet, Jan-Paul Bohn, et al.
Pageof 6